Loading Events

« All Events

  • This event has passed.

Advances in Technology for Cardiovascular Diseases

February 3, 2021 @ 4:00 pm - 6:00 pm EST


Full Length

Cardiovascular diseases are the leading cause of death globally–comprising ~30% of all deaths (WHO). This forum will highlight novel cardiac surgery devices being developed in Canada, Austria, and USA/Germany.

Feb 3, 2021
4:00 – 6:00 PM (EDT)

United States

William Munger


Cardiovascular diseases are the leading cause of death globally, comprising ~30% of all deaths (WHO)

This forum will highlight novel devices being developed in Canada, Austria, and USA for treating:

  • Advanced heart failure
  • Atrial fibrillation
  • Heart valve replacement
  • Thrombi removal

Wed, Feb 3, 4:00 – 6:00pm (EST)
4:00 – 4:30 General Networking
4:30 – 5:30 Panelist Presentations
5:30 – 6:00 ‘Meet the Speakers’ & More Networking

Forum Fees
$0 – Members (all categories)
$0 – Sponsors / Student
$0 – Covid Hardship
$20 – Non-Member

Kardium Inc. has developed an advanced system for the treatment of atrial fibrillation (AF), which affects more than 37 million people worldwide. Its mapping and ablation treatment is the most complete solution for AF, offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation – all in a single catheter.

Abiomed Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure.

Angel Valve Vienna (AVVie) develops novel, minimally invasive repair systems addressing mitral insufficiency, a clinically unmet need correcting heart valve dysfunction, affecting millions worldwide. The Mitral Butterfly implant is based on a unique physiological design which can be deployed in one-step via a minimally invasive transcatheter procedure.

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices designed to improve patient outcomes while lowering costs for healthcare providers. The AngioVac System can be used for the removal of commonly encountered undesirable intravascular material.




Kevin Chaplin
CEO, Kardium Inc

Kevin has been at Kardium Inc for 13 years in various roles and is now CEO and leading the company through it’s first commercial procedures. Kevin has a B.Sc. in Chemical Engineering from the University of Cape Town.



Sonya Bhavsar, PhD
Associate Director, Surgical & Pediatrics Platform, Abiomed Inc

Sonya’s team of engineers is focused on innovating heart pump technologies to support patients with acute and advanced heart failure. She completed her PhD at the Helmholtz Institute, RWTH Aachen University in Aachen, Germany.



Prof. Werner Mohl, MD, PhD
Founder, AVVie GmbH

As founder, Dr. Mohl has more than 40 years experience in research, patient care, and medical education in the cardiovascular field.He is an inventor and co-inventor of many medtech patents along with the PISCO concept, & founder of Miracor Medical.



Johanna Ticar, MSc
Project Manager, AVVie GmbH

An R&D biomedical engineer with experience in design verification testing, preclinical studies, project planning, etc., Johanna is managing projects for AVVie. Previously at Xeltis in Eindhoven, she helped develop biodegradable heart valves.



Kelly Burke, PMP
Sr. R&D Program Manager, AngioDynamics

Kelly joined AngioDynamics in 2018, with 15+ years experience in the medical device industry. She is currently focused on program management of the AngioVac portfolio with projects ranging from product enhancements to new product launches.




Andrea Cahill
Systems Engineer, Boston Scientific Director, MDG Boston




Urvi Kanakaraj, MS
Software QA Engineer, PathAI






February 3, 2021 Forum


February 3, 2021
4:00 pm - 6:00 pm EST
Event Categories:




MDG Boston